Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:21 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
NCT01347866 · Pfizer · PHASE1 · terminated · last registry update 2018-10-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Refer to Detailed Description for documentaion of Termination Statement.” | – | Registry record, Pfizer |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MTOR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-10-29Results posted on the registry: Memorial Sloan Kettering Cancer Center, MLN0128 (NCT02091531)
- 2019-10-25Phase 3 first posted: Restorbio Inc., Dactolisib + Placebo (NCT04139915)
- 2019-10-04Also stopped (terminated): University of Florida, Gedatolisib + Paclitaxel (NCT02920450)
- 2019-10-03Results posted on the registry: University of Florida, Gedatolisib + Paclitaxel (NCT02920450)
- 2019-08-08Results posted on the registry: Millennium Pharmaceuticals, Inc., MLN0128 + paclitaxel (NCT01351350)
- 2019-06-11Results posted on the registry: Sanofi, SAR245408 + SAR245409 (NCT01587040)
- 2019-05-20Also stopped (terminated): Samsung Medical Center, AZD2014 (NCT03061708)
- 2019-05-20Also stopped (withdrawn): Samsung Medical Center, Vistusertib(AZD2014) (NCT03166176)
- 2019-05-20Also stopped (terminated): Samsung Medical Center, AZD5363 + paclitaxel (NCT02449655)
- 2019-05-20Also stopped (withdrawn): Samsung Medical Center, Vistusertib(AZD2014) (NCT03166904)
- 2019-05-20Also stopped (terminated): Samsung Medical Center, AZD2014 (NCT03082833)
- 2019-05-06Results posted on the registry: Merck Sharp & Dohme LLC, Ridaforolimus 100 mg + Ridaforolimus 40 mg (NCT00874731)
- 2019-04-19Results posted on the registry: Merck Sharp & Dohme LLC, ridaforolimus (NCT01380184)
- 2019-04-10Also stopped (terminated): Cliniques universitaires Saint-Luc- Université Catholique de Louvain, BEZ235 (NCT01856101)
- 2019-03-25Results posted on the registry: Merck Sharp & Dohme LLC, Ridaforolimus + Dalotuzumab (NCT01605396)
- 2019-03-01Results posted on the registry: Merck Sharp & Dohme LLC, Ridaforolimus (NCT01431534)
- 2019-03-01Also stopped (terminated): Merck Sharp & Dohme LLC, Ridaforolimus (NCT01431534)
- 2019-02-18Also stopped (terminated): Merck Sharp & Dohme LLC, Ridaforolimus Tablet + Ridaforolimus Intravenous (IV) Infusion (NCT00836927)
- 2019-01-08Also stopped (terminated): Pfizer, PF-05212384 + PF-05212384 (NCT01420081)
- 2019-01-08Also stopped (terminated): Pfizer, PF-05212384 + irinotecan (NCT01925274)
- 2018-11-02Results posted on the registry: Pfizer, PF-05212384 (also known as PKI-587) (NCT00940498)
- 2018-10-17Results posted on the registry: AstraZeneca, AZD2014 + Fulvestrant (NCT01597388)
- 2018-09-20Also stopped (terminated): Samsung Medical Center, vistusertib (AZD2014) (NCT03106155)
- 2018-08-16Also stopped (terminated): Merck Sharp & Dohme LLC, dalotuzumab + MK-0752 (NCT01243762)
- 2018-05-03Results posted on the registry: Merck Sharp & Dohme LLC, Ridaforolimus Tablet + Ridaforolimus Intravenous (IV) Infusion (NCT00836927)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision